BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Acetaminophen
,
rs4950928
,
GATA1
,
Fatty acid metabolic process
,
Lung cancer
,
Neuron
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
DAF 2
Summary
General Info
Curated Studies
Most Correlated Studies
C. elegans responses to DNA damage and starvation in xpa-1, daf-2 and daf-16 mutant L1 larvae
C. elegans mutants with longevity phenotype (rsks-1, daf-2, daf-16)
Late L4 stage C. elegans with daf-2 loss-of-function mutation and daf-16 or pmk-1 deletions
Whole animal at young adult stage with GLP-1, DAF-2, & DAF-16 mutation affecting longevity
Expression analysis of ER stress response in C. elegans
Explore Curated Studies Results
Literature
Most Relevant Literature
IGF/IGF-1R signal pathway in pain: a promising therapeutic target.
Cryo-EM studies of the apo states of human IGF1R.
Decreased IGF1R attenuates senescence and improves function in pancreatic β-cells.
Association of IGF1R polymorphisms with kidney function-related traits.
Exosomal miR-223 promotes ARDS by targeting insulin-like growth factor 1 receptor: A cell communicat…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Expression of Sodium-glucose Co-transporter 2 in Human Heart
Nutrigenomics Investigation of the Body's Metabolic Response to 2 Different Meal Challenges
Study of the Effect of Beta-3 Adrenergic Receptor Agonists on Oxidative Stress and Signalling Pathwa…
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maint…
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ